Home / Investors / Overview

Company Information

CymaBay Therapeutics (Nasdaq: CBAY)

We are a clinical-stage biopharmaceutical company focused on developing and providing access to innovative therapies for patients with liver and other chronic diseases with high unmet medical need. We are evaluating seladelpar in primary biliary cholangitis (PBC). We also have two product programs in earlier development that feature unique mechanisms of action and have potential in liver and chronic diseases.

Stock Information

Last Change Volume

Shares Outstanding: 10,064,495
(as of March 3, 2014)

Company Information

CymaBay Therapeutics
7575 Gateway Blvd
Suite 110
Newark, CA 94560

Investor Relations

LifeSci Advisors, LLC
Hans Vitzthum
(617) 430-7578

Recent News


CymaBay Therapeutics to Present at Upcoming Investor Conferences


CymaBay Reports Second Quarter and Six Months Ended June 30, 2021 Financial Results and Provides Corporate Update


CymaBay Therapeutics to Report Second Quarter 2021 Financial Results on Thursday, August 12, 2021

Upcoming Event

Sep 28 2021 3:20PM ET

2021 Cantor Virtual Global Healthcare Conference

September 28, 2021 at 3:20PM ET

Q2 2021 Quarterly Results